Descripción del proyecto
Un diagnóstico mejorado podría arrojar luz sobre la deficiencia de vitamina D
En la actualidad, cada vez más pruebas demuestran las importantes funciones que tiene la vitamina D en los tejidos no óseos y cómo una cantidad inadecuada de ella puede afectar a procesos que van desde el cáncer hasta las enfermedades cardiovasculares. Además, es probable que las cantidades necesarias para la salud sean mayores de lo que se pensaba. Al mismo tiempo, siguen aumentando los casos de deficiencia o insuficiencia de vitamina D. Aunque las estimaciones varían, las pruebas sugieren que más de mil millones de personas en todo el mundo (más del 10 % de la población) tienen deficiencia o insuficiencia de vitamina D. OSAvit-D está desarrollando un dispositivo rentable de diagnóstico en el punto de atención para realizar un cribaje generalizado sobre esta cuestión durante las visitas ambulatorias. Esto mejorará y permitirá la detección temprana y el tratamiento de las cada vez más comunes deficiencias de vitamina D potencialmente dañinas.
Objetivo
OSASEN is a young technological SME focused on the development of novel biosensors for healthcare (Point of Care-PoC devices), addressing priority needs in healthcare diagnostics and/or therapies monitoring for the benefit of patients, providing affordable systems with unique features that meet specific well identified requirements in healthcare. OSASEN has recently identified a healthcare need in relation with prevention, treatment and monitoring of Vitamin D (VitD) deficiency. VitD (1,25-DihydroxyvitaminD) is considered a multipurpose steroid hormone that in human plays an essential role in multiple aspects, being its primary role to participate in the regulation of metabolism of calcium and phosphorous. VitD deficiency is evident throughout the European population at a prevalence of 13% (FP7-613977-ODIN project), a rate that is a matter of concern. People over 50 have an increased risk of vitamin D deficiency with consequent bone loss risk leading to osteoporosis and fractures. Emerging evidence has shown that VitD administration improves muscle performance and reduces falls in VitD deficient older adults. Other populations of higher risk for VitD deficiency are children, pregnant and lactating women and patients with digestive disorders, among others. VitD deficiency is also associated with increased risk of cancer, cardiovascular disease, infections, and autoimmune diseases. For example, several studies have shown that VitD levels are lower in Multiple Sclerosis patients, and monitoring and VitD supplementation to them is highly recommended. In this context, OSASEN has identified the opportunity to develop a novel PoC device for the quantification of VitD in blood or urine based on lateral flow (LF) immunoassay, combined with electrochemical detection on screen printed electrodes (SPEs). For doing so, it is necessary to incorporate an expert in LF immunoassays and antibody selection, conjugation, handling & stabilization to OSASEN’s team.
Ámbito científico
Not validated
Not validated
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensorsbiosensors
- medical and health sciencesbasic medicineneurologymultiple sclerosis
- medical and health sciencesbasic medicineimmunologyautoimmune diseases
- medical and health sciencesclinical medicinecardiologycardiovascular diseases
- medical and health sciencesclinical medicineoncology
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-INNOSUP-2019-02
Régimen de financiación
CSA - Coordination and support actionCoordinador
48160 DERIO
España
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.